Halozyme Therapeutics (HALO) Tops Q2 EPS by 26c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $131.18 --0%
EPS Growth %: +32.6%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
TFS, PBNK, FNRN, More
EPS Growth %: +32.6%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
TFS, PBNK, FNRN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.66, $0.26 better than the analyst estimate of $0.40. Revenue for the quarter came in at $136.5 million versus the consensus estimate of $103.16 million.
GUIDANCE:
Halozyme Therapeutics sees FY2021 EPS of $1.85-$2.00, versus the consensus of $1.41. Halozyme Therapeutics sees FY2021 revenue of $425-445 million, versus the consensus of $404.6 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TFS Financial (TFSL) Reports In-Line Q4 EPS
- BCB Bancorp (BCBP) Tops Q3 EPS by 245c
- AstraZeneca (AZN) Tops Q3 EPS by 20c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
